212 related articles for article (PubMed ID: 11889904)
1. In vivo studies of monoclonal anti-D and the mechanism of immune suppression.
Kumpel BM
Transfus Clin Biol; 2002 Jan; 9(1):9-14. PubMed ID: 11889904
[TBL] [Abstract][Full Text] [Related]
2. Monoclonal anti-D development programme.
Kumpel BM
Transpl Immunol; 2002 Aug; 10(2-3):199-204. PubMed ID: 12216950
[TBL] [Abstract][Full Text] [Related]
3. Monoclonal anti-D for prophylaxis of RhD haemolytic disease of the newborn.
Kumpel BM
Transfus Clin Biol; 1997 Jul; 4(4):351-6. PubMed ID: 9269715
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of anti-D action in the prevention of hemolytic disease of the fetus and newborn.
Brinc D; Lazarus AH
Hematology Am Soc Hematol Educ Program; 2009; ():185-91. PubMed ID: 20008198
[TBL] [Abstract][Full Text] [Related]
5. Human Rh D monoclonal antibodies (BRAD-3 and BRAD-5) cause accelerated clearance of Rh D+ red blood cells and suppression of Rh D immunization in Rh D- volunteers.
Kumpel BM; Goodrick MJ; Pamphilon DH; Fraser ID; Poole GD; Morse C; Standen GR; Chapman GE; Thomas DP; Anstee DJ
Blood; 1995 Sep; 86(5):1701-9. PubMed ID: 7655002
[TBL] [Abstract][Full Text] [Related]
6. The introduction of human monoclonal anti-D for therapeutic use.
Fletcher A; Thomson A
Transfus Med Rev; 1995 Oct; 9(4):314-26. PubMed ID: 8541714
[No Abstract] [Full Text] [Related]
7. On the mechanism of tolerance to the Rh D antigen mediated by passive anti-D (Rh D prophylaxis).
Kumpel BM
Immunol Lett; 2002 Jun; 82(1-2):67-73. PubMed ID: 12008036
[TBL] [Abstract][Full Text] [Related]
8. Plasma half-lives and bioavailability of human monoclonal Rh D antibodies BRAD-3 and BRAD-5 following intramuscular injection into Rh D-negative volunteers.
Goodrick J; Kumpel B; Pamphilon D; Fraser I; Chapman G; Dawes B; Anstee D
Clin Exp Immunol; 1994 Oct; 98(1):17-20. PubMed ID: 7923878
[TBL] [Abstract][Full Text] [Related]
9. The role of Rh antibodies in haemolytic disease of the newborn.
Hadley AG; Kumpel BM
Baillieres Clin Haematol; 1993 Jun; 6(2):423-44. PubMed ID: 8043933
[TBL] [Abstract][Full Text] [Related]
10. In vitro functional activity of IgG1 and IgG3 polyclonal and monoclonal anti-D.
Kumpel BM
Vox Sang; 1997; 72(1):45-51. PubMed ID: 9031501
[TBL] [Abstract][Full Text] [Related]
11. Section 1C: Assessment of the functional activity and IgG Fc receptor utilisation of 64 IgG Rh monoclonal antibodies. Coordinator's report.
Kumpel BM; Beliard R; Brossard Y; Edelman L; de Haas M; Jackson DJ; Kooyman P; Ligthart PC; Monchâtre E; Overbeeke MA; Puillandre P; de Romeuf C; Wilkes AM
Transfus Clin Biol; 2002 Jan; 9(1):45-53. PubMed ID: 11889899
[TBL] [Abstract][Full Text] [Related]
12. Mechanism of anti-D-mediated immune suppression--a paradox awaiting resolution?
Kumpel BM; Elson CJ
Trends Immunol; 2001 Jan; 22(1):26-31. PubMed ID: 11286688
[TBL] [Abstract][Full Text] [Related]
13. Quantification of IgG anti-D bound to D-positive red cells infused into D-negative subjects after intramuscular injection of monoclonal anti-D.
Kumpel BM; Judson PA
Transfus Med; 1995 Jun; 5(2):105-12. PubMed ID: 7655572
[TBL] [Abstract][Full Text] [Related]
14. The functional activity of human monocytes passively sensitized with monoclonal anti-D suggests a novel role for Fc gamma RI in the immune destruction of blood cells.
Griffiths HL; Kumpel BM; Elson CJ; Hadley AG
Immunology; 1994 Nov; 83(3):370-7. PubMed ID: 7835961
[TBL] [Abstract][Full Text] [Related]
15. Monoclonal anti-D for immunoprophylaxis.
Scott ML
Vox Sang; 2001 Nov; 81(4):213-8. PubMed ID: 11903995
[TBL] [Abstract][Full Text] [Related]
16. Effect of producer cell line on functional activity of anti-D monoclonal antibodies destined for prevention of rhesus sensitization.
Olovnikova NI; Ershler MA; Belkina EV; Nikolaeva TL; Miterev GY
Bull Exp Biol Med; 2009 Apr; 147(4):448-52. PubMed ID: 19704946
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of RhD monoclonal antibodies in clinical trials as replacement therapy for prophylactic anti-D immunoglobulin: more questions than answers.
Kumpel BM
Vox Sang; 2007 Aug; 93(2):99-111. PubMed ID: 17683353
[TBL] [Abstract][Full Text] [Related]
18. [Anti-Rho[D] antigen monoclonal antibodies. II. Serological characteristics of monoclonal IgG1 antibodies].
Olovnikova NI; Belkina EV; Lemeneva LN; Berkovskiĭ AL; Deriugina EI; Chertkov IL
Gematol Transfuziol; 1992; 37(9-10):5-9. PubMed ID: 1490578
[TBL] [Abstract][Full Text] [Related]
19. Lessons learnt from many years of experience using anti-D in humans for prevention of RhD immunization and haemolytic disease of the fetus and newborn.
Kumpel BM
Clin Exp Immunol; 2008 Oct; 154(1):1-5. PubMed ID: 18727626
[TBL] [Abstract][Full Text] [Related]
20. Clearance of red cells by monoclonal IgG3 anti-D in vivo is affected by the VF polymorphism of Fcgamma RIIIa (CD16).
Kumpel BM; De Haas M; Koene HR; Van De Winkel JG; Goodrick MJ
Clin Exp Immunol; 2003 Apr; 132(1):81-6. PubMed ID: 12653840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
